SCHEMBL4427488

SCHEMBL4427488

Cc1cc(-c2ccccc2)ccc1C(=O)Nc1ccc2cccnc2c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.61
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
NOTUM Q6P988 1/20 0.53
MMP9 P14780 1/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
PABPC1 P11940 1/20 0.50
POLB P06746 1/20 0.50
MCHR1 Q99705 1/20 0.48
MAPT P10636 1/20 0.48
P2RY14 Q15391 2/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
EGLN1 Q9GZT9 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4435934 0.86 NPC1 (0.59) TRPV1MEN1KMT2ANOTUMNPC1
SCHEMBL4428905 0.86 TRPV1 (0.76) TRPV1MEN1KMT2AMMP9NPC1
SCHEMBL4422133 0.83 TRPV1 (0.66) TRPV1MEN1KMT2ANOTUMNPC1
SCHEMBL4428142 0.82 MEN1 (0.65) TRPV1MEN1KMT2AMMP9NPC1
SCHEMBL4428117 0.81 TRPV1 (0.66) TRPV1MEN1KMT2ANOTUMMMP9
SCHEMBL4423337 0.80 MEN1 (0.65) TRPV1MEN1KMT2AMMP9NPC1
SCHEMBL4432764 0.80 MEN1 (0.65) TRPV1MEN1KMT2ANOTUMMMP9
SCHEMBL18132530 0.79 MEN1 (0.61) TRPV1MEN1KMT2ANOTUMNPC1
SCHEMBL4427491 0.78 MEN1 (0.67) TRPV1MEN1KMT2ANOTUMMMP9
SCHEMBL7101847 0.78 PABPC1 (0.79) TRPV1MEN1KMT2ANOTUMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 TRPV1 1/4885MEN1 3527/4885KMT2A 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.